Azithromycin

Zoliflodacin, an investigational single-dose oral antibiotic for uncomplicated gonorrhea, to be featured in oral presentation with key subset analyses from pivotal global Phase 3 trial Waltham, MA – October 20, 2025 – Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), will share new data on zoliflodacin during the Infectious Disease Society of America’s IDWeek 2025 annual meeting in Atlanta, GA, October 19-22, 2025. Zoliflodacin is a first-in-class oral antibiotic being developed for the treatment of uncomplicated gonorrhea. Three sets of data will be presented, including an oral presentation and two poster presentations: Poster Presentation P-1206 Date: Tuesday, October 21, 2025 Time: 12:15 PM – 1:30 PM ET Location: Poster Hall B4-B5 Title: Association of Sex Assigned at Birth and Sexual Orientation with Antimicrobial Susceptibility of Baseline Neisseria gonorrhoeae Isolates from Participants Recruited in the Global Zoliflodacin Phase 3 Randomized Controlled Trial Poster Presentation P-1207 Date: Tuesday, October 21, 2025 Time: 12:15 PM – 1:30 PM ET Location: Poster Hall B4-B5 Title: In Vitro Activity of Zoliflodacin against Neisseria gonorrhoeae Isolates Collected in 2022 from The United States Oral Presentation Date: Wednesday, October 22, 2025 Time: 1:45-3:00 Location: B211-B212 Title: Subgroup Analyses of Microbiological Cure Rates by Baseline Zoliflodacin MIC and Susceptibility to Ciprofloxacin in Participants from the Global Zoliflodacin Phase 3 Randomize Controlled Trial The oral presentation on Wednesday, October 22, describes key subgroup findings from the pivotal Phase 3 trial, including observation of high microbiological cure rates across urogenital, rectal, and pharyngeal sites in infection caused by Neisseria gonorrhoeae with a zoliflodacin MIC of ≤0.25 µg/mL. Among participants with urogenital infections who received zoliflodacin, ciprofloxacin-resistant strains had a cure rate of 96.6% (346/358; 95% CI: 94.2–98.3) and ciprofloxacin-susceptible strains had a cure rate of 97.4% (113/116; 95% CI: 92.6–99.5). High cure rates were consistent regardless of infection site. In poster P-1206 to be presented on Tuesday October 21, a demographic analysis of baseline isolates from the zoliflodacin Phase 3 trial found that while azithromycin resistance was higher in isolates from men who have sex with men (MSM), zoliflodacin MIC values were comparable across all patient groups, including females, MSM and heterosexual men (HSM). These findings underscore the in vitro activity of zoliflodacin across antibiotic-resistant N. gonorrhoeae from a broad range of sources and support the continued development of zoliflodacin as a single, oral dose treatment for uncomplicated gonorrhea. “Findings from our analyses reinforce our initial conclusions and support the development of zoliflodacin as a potentially transformative treatment for gonorrhea, including infections caused by resistant strains,” stated Dr. David Altarac, Chief Medical Officer of Innoviva Specialty Therapeutics. “Achieving high and consistent cure rates across urogenital and extra-genital sites, resistance profiles, and patient demographics represents a significant opportunity to address the growing global threat of antibiotic-resistant Neisseria gonorrhoeae.” Complementary analyses presented in poster P-1207 further support the potential of zoliflodacin as a broadly effective treatment for gonorrhea. In vitro susceptibility testing of Neisseria gonorrhoeae clinical isolates collected in the U.S. during 2022 confirmed that zoliflodacin potency remained consistent compared to prior surveillance years (2020–2021), including against antibiotic-resistant strains and isolates from both male and female patients. “The results from all three presentations show that zoliflodacin mechanism of action is differentiated from fluoroquinolones with cure rates remaining high in the face of antibiotic resistance,” said Dr. Sarah McLeod, Senior Director, Innoviva Specialty Therapeutics. About Zoliflodacin Zoliflodacin is an investigational, first-in-class oral antibiotic from the spiropyrimidinetrione class, currently in development as a single-dose treatment for uncomplicated gonorrhea, including strains resistant to current first-line therapies. Zoliflodacin inhibits bacterial DNA gyrase, an essential enzyme for bacterial survival. Zoliflodacin mechanism of action is distinct from that of currently approved antibiotics and has demonstrated activity against drug-resistant Neisseria gonorrhoeae. Non-inferiority was demonstrated in the global Phase 3 trial (NCT03959527) where a single oral dose of zoliflodacin was compared to ceftriaxone plus azithromycin for uncomplicated urogenital gonorrhea. This trial was sponsored by the Global Antibiotic Research and Development Partnership (GARDP). The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows FDA Priority Review and Extended Market Exclusivity. Innoviva Specialty Therapeutics, Inc., anticipates that the NDA review will proceed according to the standard process for drugs with this designation. About Innoviva Specialty Therapeutics Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., is focused on delivering innovative therapies in critical care and infectious disease. Innoviva Specialty Therapeutics’ products, through its affiliate, La Jolla Pharmaceutical Company, include GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Innoviva Specialty Therapeutics’ products, through its affiliate, Entasis Therapeutics Inc., include XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). ZEVTERA® (ceftobiprole) is an FDA-approved cephalosporin specifically designed to treat adult patients with acute bacterial skin and skin structure infections (ABSSSI), adult patients with Staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis, and adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP). The Company’s clinical pipeline includes zoliflodacin, an investigational antibiotic for uncomplicated gonorrhea, which is being developed in collaboration with the Global Antibiotic Research and Development Partnership (GARDP), and is currently under review by the U.S. Food and Drug Administration. For more information about Innoviva Specialty Therapeutics, please visit here. Forward Looking Statements This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, formerly, TRELEGY® ELLIPTA® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives beyond the existing respiratory portfolio); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus (COVID-19). Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31, 2022 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law. Media Contact: David Patti Corporate Communications Innoviva, Inc. david.patti@inva.com Investor Contact: Eleanor Barisser Eleanor.barisser@inva.com

HOUSTON, TEXAS, TX, UNITED STATES, October 7, 2025 / EINPresswire.com / -- NORWOOD Device & Diagnostics, a privately-held ophthalmic device company developer of the Nighthawk™ and Nighthawk™ Pro slit lamps incorporating Dry Eye imaging and Anterior Segment diagnostics, is pleased to announce a strategic co-marketing and sales agreement has been reached with OCuSOFT Inc., a company recognized as developing the first eyelid hygiene cleansing agent. With increased interest in Dry Eye and Ocular Surface Disease, the Nighthawk™ Pro Model goes even further to provide Dry Eye diagnostic testing including tear meniscus height, non- invasive tear breakup time and lipid layer analysis. While the Nighthawk™ Dry Eye and Imaging systems can accurately diagnose various Dry Eye conditions, the wide-ranging therapeutic Dry Eye therapy products offered by OCuSOFT ® can address these conditions offering the practitioner a full circle of care from diagnosis to treatment options. Rick Norwood, President and founder of NORWOOD Device and Diagnostics states “NORWOOD Device has grown steadily over the years; however, I have always thought with the right partner, NORWOOD could go even further in reaching its true potential. Finding that right partner was the key; someone that we could trust and go “all-in” with. We believe we have the right partner with OCuSOFT ® which has, from the beginning of their business, been an innovator. We are delighted to join forces with them to deliver full circle Dry Eye care from diagnosis to treatment.” Cynthia Barratt, CEO and co-founder of OCuSOFT Inc. spoke similarly in describing the NORWOOD/OCuSOFT ® relationship: “By sheer serendipity, I met Rick on a plane ride to a trade show in Las Vegas. That chance meeting gave me and my co-founder, Nat Adkins, our Executive Chairman, the opportunity to get to know Rick and his business. While the business synergies were obvious, Rick’s character and humble beginnings, like ours, gave us both the comfort to know this was the right relationship at the right time”, she concluded. About NORWOOD Device & Diagnostics Founded in 2009, Norwood Device & Diagnostics is a trusted partner to independent Eye Care Professionals (ECPs) across the United States, providing high-quality diagnostic equipment, medical devices, and exam lane solutions. Led by Rick Norwood, who brings nearly 39 years of ophthalmic industry experience and strong global manufacturing relationships, the company is dedicated to delivering innovation, precision, and exceptional service. Since 1986, Rick has spent 18 years on the Optical and Finishing side of Optometry and the last 20 years focused on Diagnostics. As an exclusive importer and distributor, Norwood specializes in the Dry Eye (DE) space, offering a curated portfolio of products—including its flagship Nighthawk™ and Nighthawk™ Pro digital imaging slit lamps—and DED-focused objective testing instruments that enable clinicians to accurately assess and manage ocular surface disease for improved patient outcomes. With a commitment to integrity, customer-focused service, and bridging international innovation with U.S. eye care delivery, Norwood Device & Diagnostics continues to support ECPs in providing outstanding vision care. For more information on NORWOOD Device & Diagnostics: Contact: Rick Norwood, President Phone: (855) 370-1900 Email: customerservice@nvisiongroupusa.com About OCuSOFT Inc. OCuSOFT Inc. is a privately-held company widely known for its OCuSOFT ® Lid Scrub ® (OLS) family of eyelid hygiene products. OCuSOFT Inc. offers a complete line of eye care products including not only the OLS hygiene group but also Retaine ® MGD ® Advanced™ preservative-free artificial tears, Retaine ® CMC ® , HypoChlor ® Spray, and many others. OCuSOFT Inc. established the Southwest Research & Technology Center which houses numerous eye care related companies including Primera Research Pharma, LLC. Through a licensing agreement, Primera Compounding, LLC developed the first medicated eyelid cleanser containing both OLS coupled with azithromycin, now available through prescription as Biune™ Eyelid Spray. For more information on OCuSOFT Inc.: Contact: George Haines, Executive Vice President Phone: (800) 233-5469 Email: ghaines@ocusoft.com Rick Norwood Norwood Device & Diagnostics +1 855-370-1900 email us here Visit us on social media: Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.